Immunotherapy for Infectious Diseases

58 Boyaka and McGhee
133. Gill DM. The arrangement of subunits in cholera toxin. Biochemistry 1976; 15:1242–1248.
134. Spangler BD. Structure and function of cholera toxin and the related Escherichia coli heatlabile
enterotoxin. Microbiol Rev 1992; 56:622–647.
135. Heyningen SV. Cholera toxin: interaction of subunits with ganglioside GM1. Science
1974; 183:656–657.
136. Field M, Rao MC, Chang EB. Intestinal electrolyte transport and diarrheal disease (1). N
Engl J Med 1989; 321:800–806.
137. Dallas WS, Falkow S. Amino acid sequence homology between cholera toxin and
Escherichia coli heat-labile toxin. Nature 1980; 288:499–501.
138. Tsuji T, Inoue T, Miyama A, Okamoto K, Honda T, Miwatani T. A single amino acid substitution
in the A subunit of Escherichia coli enterotoxin results in a loss of its toxic activity.
J Biol Chem 1990; 265:22520–22525.
139. Harford S, Dykes CW, Hobden AN, Read MJ, Halliday IJ. Inactivation of the Escherichia
coli heat-labile enterotoxin by in vitro mutagenesis of the A-subunit gene. Eur J Biochem
1989; 183:311–316.
140. Yamamoto S, Takeda Y, Yamamoto M, et al. Mutants in the ADP-ribosyltransferase cleft
of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med 1997;
185:1203–1210.
141. Yamamoto S, Kiyono H, Yamamoto M, et al. A nontoxic mutant of cholera toxin elicits
Th2-type responses for enhanced mucosal immunity. Pro Natl Acad Sci USA 1997;
94:5267–5272.
142. Yamamoto M, Kiyono H, Yamamoto S, et al. Direct effects on antigen-presenting cells
and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. J Immunol
1999; 162:7015–7021.
143. Cong Y, Weaver CT, Elson CO. The mucosal adjuvanticity of cholera toxin involves
enhancement of costimulatory activity by selective upregulation of B7.2 expression. J
Immunol 1997; 159:5301–5308.
144. Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G. Intranasal immunogenicity and
adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun 1997;
65:2821–2828.
145. Douce G, Turcotte C, Cropley I, et al. Mutants of Escherichia coli heat-labile toxin lacking
ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad
Sci USA 1995; 92:1644–1648.
146. Giuliani MM, Del Giudice G, Giannelli V, et al. Mucosal adjuvanticity and immunogenicity
of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial
knockout of ADP-ribosyltransferase activity. J Exp Med 1998; 187:1123–1132.
147. Rappuoli R, Pizza M, Douce G, Dougan G. Structure and mucosal adjuvanticity of cholera
and Escherichia coli heat-labile enterotoxins. Immunol Today 1999; 20:493–500.
148. Takahashi I, Marinaro M, Kiyono H, et al. Mechanisms for mucosal immunogenicity
and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis 1996; 173, no. 3:
627–635.
149. Agren LC, Ekman L, Lowenadler B, Lycke NY. Genetically engineered nontoxic vaccine
adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
J Immunol 1997; 158:3936–3946.
150. Agren L, Sverremark E, Ekman L, et al. The ADP-ribosylating CTA1-DD adjuvant
enhances T cell-dependent and independent responses by direct action on B cells involving
anti-apoptotic Bcl-2- and germinal center-promoting effects. J Immunol 2000;
164:6276–6286.
151. Agren LC, Ekman L, Lowenadler B, Nedrud JG, Lycke NY. Adjuvanticity of the cholera
toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADPribosyltransferase
and Ig-binding activity. J Immunol 1999; 162:2432–2440.